Protherabiologics
1 known investors
ProThera Biologics develops therapies based on Inter-alpha inhibitor proteins (IAIP), a class of human plasma proteins with anti-inflammatory activity, to treat patients with severe inflammatory diseases. The company targets life-threatening immune responses associated with high mortality in intensive care settings.
BiotechHealthtech